登录 | 注册    关注公众号  
微信公众号
搜索
 > 【TFPI】

TFPI信息

英文名称:Tissue factor pathway inhibitor
中文名称:组织因子通道抑制剂
靶点别称:TFPI,Tissue Factor Pathway Inhibitor,Extrinsic Pathway Inhibitor,TFPI1,LACI,EPI,Anti-Convertin,TFI,Lipoprotein-associated coagulation inhibitor,Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor)
上市药物数量:1
临床药物数量:4
最高研发阶段:批准上市

TFPI 分子别名

TFPI,LACI,TFPI1,EPI,TFI

TFPI 分子背景

Tissue factor pathway inhibitor (TFPI) is also known as Extrinsic pathway inhibitor (EPI), Lipoprotein - associated coagulation inhibitor (LACI), is a plasma proteinase inhibitor synthesized by vascular endothelial cells and part of it is associated with glycosaminoglycans of these cells. TFPI is a single-chain polypeptide which can reversibly inhibit Factor Xa (Xa) and Thrombin (Factor IIa). TFPI is a secreted protein with a N­terminal acidic region, three Kunitz (K) domains separated with by two linker regions, and a C­terminal basic region. The first K domain inhibits coagulation factor VIIa complexed to tissue factor (TF); The second K domain inhibits factor Xa; The third K domain binds to heparin; The C­terminal basic region may have several functions. For example, it plays an important role in binding of TFPI to cell surfaces.

TFPI 前沿进展

TFPI上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验

TFPI临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验

消息提示

请输入您的联系方式,再点击提交!

确定